NCT01870427View on ClinicalTrials.gov

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2016

Conditions
Macular Edema With Central Retinal Vein Occlusions
Interventions
DRUG

Aflibercept (2.0 mg)

Intravitreal Aflibercept (2.0 mg)

Trial Locations (1)

94040

Northern California Retina Vitreous Associates, Mountain View

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Northern California Retina Vitreous Associates

OTHER

NCT01870427 - NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions | Biotech Hunter | Biotech Hunter